Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment-Reference-Cited by-同舟云学术

Design, synthesis and biological evaluation of potent epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors against resistance mutation for lung cancer treatment

Published:2024-02 Issue: Volume:143 Page:107004
ISSN:0045-2068
Container-title:Bioorganic Chemistry
language:en
Short-container-title:Bioorganic Chemistry

Author:

Wang Cheng,Wang Xin,Wang Xiaoxue,Tian Baorui,Zhang Sihe,Wang Tianqi,Ma Yakun,Fan Yan

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry

Reference41 articles.

1. Cancer statistics, 2022;Siegel;CA Cancer J. Clin.,2022

2. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008

3. Lung cancer;Herbst;N. Engl. J. Med.,2008

4. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;New Engl. J. Med.,2009

5. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat. Rev. Cancer,2007

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer;European Journal of Medicinal Chemistry;2024-11

2. Characterization and Cytotoxic Assessment of Bis(2-hydroxy-3-carboxyphenyl)methane and Its Nickel(II) Complex;Molecules;2024-09-06

3. High throughput virtual screening and validation of Plant-Based EGFR L858R kinase inhibitors against Non-Small cell lung Cancer: An integrated approach Utilizing GC–MS, network Pharmacology, Docking, and molecular dynamics;Saudi Pharmaceutical Journal;2024-09

4. Synthesis, in-vitro and molecular docking studies of 3,4- dihydropyrmidine-2-(1H) one-based Calix[4]arenes as antimicrobial agent and kinase inhibitor;Journal of Molecular Structure;2024-09

5. Current scenario of fused pyrimidines with in vivo anticancer therapeutic potential;Archiv der Pharmazie;2024-05-16